Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock

Seema Thakral; Andrea Wolf; Gregory J. Beilman; Raj Suryanarayanan

doi:10.1016/j.ijpharm.2017.12.024

Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock

Seema Thakral, Andrea Wolf, Gregory J. Beilman, Raj Suryanarayanan

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Hemorrhagic shock, caused by trauma, is a leading cause of preventable death. A combination treatment of D-β-hydroxybutyrate (BHB) and melatonin (MLT), in dimethyl sulfoxide - water, increased survival. A freeze-dried BHB–MLT formulation, with a short reconstitution time, has been developed. This intravenous formulation, prepared with an aqueous vehicle, completely eliminated dimethyl sulfoxide, thereby avoiding the potential problems associated with this solvent. The poor aqueous solubility of MLT necessitated the use of polyvinylpyrrolidine (PVP) as a complexing agent. Thus the prelyophilization solution contained BHB (2 M), MLT (21.5 mM) and PVP (40 mM). Using a combination of low-temperature X-ray diffractometry and thermal analysis, the lyophilization process parameters were optimized. Infra-red spectra revealed hydrogen bonding interaction between PVP and MLT, while BHB crystallized as BHB.0.25 H₂O in the final lyophile. The formulation improved survival in a rat model of hemorrhagic shock. Based on the increase in rate of survival and longer survival time compared to untreated animals, we conclude that this formulation can serve as a promising first line of treatment for hemorrhagic shock.

Original language	English (US)
Pages (from-to)	162-171
Number of pages	10
Journal	International journal of pharmaceutics
Volume	537
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ijpharm.2017.12.024
State	Published - Feb 15 2018

Bibliographical note

Funding Information:
Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ST was partially supported by the William and Mildred Peters Endowment fund . Parts of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network ( www.mrfn.org ).

Publisher Copyright:
© 2017 Elsevier B.V.

Keywords

Beta hydroxybutyrate
Hemorrhagic shock
Lyophilization
Melatonin
Resuscitation fluid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.ijpharm.2017.12.024

OpenUrl availability

Full text

Cite this

@article{0383fd68680542538448b34d5620c333,

title = "Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock",

abstract = "Hemorrhagic shock, caused by trauma, is a leading cause of preventable death. A combination treatment of D-β-hydroxybutyrate (BHB) and melatonin (MLT), in dimethyl sulfoxide - water, increased survival. A freeze-dried BHB–MLT formulation, with a short reconstitution time, has been developed. This intravenous formulation, prepared with an aqueous vehicle, completely eliminated dimethyl sulfoxide, thereby avoiding the potential problems associated with this solvent. The poor aqueous solubility of MLT necessitated the use of polyvinylpyrrolidine (PVP) as a complexing agent. Thus the prelyophilization solution contained BHB (2 M), MLT (21.5 mM) and PVP (40 mM). Using a combination of low-temperature X-ray diffractometry and thermal analysis, the lyophilization process parameters were optimized. Infra-red spectra revealed hydrogen bonding interaction between PVP and MLT, while BHB crystallized as BHB.0.25 H2O in the final lyophile. The formulation improved survival in a rat model of hemorrhagic shock. Based on the increase in rate of survival and longer survival time compared to untreated animals, we conclude that this formulation can serve as a promising first line of treatment for hemorrhagic shock.",

keywords = "Beta hydroxybutyrate, Hemorrhagic shock, Lyophilization, Melatonin, Resuscitation fluid",

author = "Seema Thakral and Andrea Wolf and Beilman, {Gregory J.} and Raj Suryanarayanan",

note = "Funding Information: Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ST was partially supported by the William and Mildred Peters Endowment fund . Parts of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network ( www.mrfn.org ). Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2018",

month = feb,

day = "15",

doi = "10.1016/j.ijpharm.2017.12.024",

language = "English (US)",

volume = "537",

pages = "162--171",

journal = "International journal of pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock

AU - Thakral, Seema

AU - Wolf, Andrea

AU - Beilman, Gregory J.

AU - Suryanarayanan, Raj

N1 - Funding Information: Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. ST was partially supported by the William and Mildred Peters Endowment fund . Parts of this work were carried out in the Characterization Facility, University of Minnesota, a member of the NSF-funded Materials Research Facilities Network ( www.mrfn.org ). Publisher Copyright: © 2017 Elsevier B.V.

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Hemorrhagic shock, caused by trauma, is a leading cause of preventable death. A combination treatment of D-β-hydroxybutyrate (BHB) and melatonin (MLT), in dimethyl sulfoxide - water, increased survival. A freeze-dried BHB–MLT formulation, with a short reconstitution time, has been developed. This intravenous formulation, prepared with an aqueous vehicle, completely eliminated dimethyl sulfoxide, thereby avoiding the potential problems associated with this solvent. The poor aqueous solubility of MLT necessitated the use of polyvinylpyrrolidine (PVP) as a complexing agent. Thus the prelyophilization solution contained BHB (2 M), MLT (21.5 mM) and PVP (40 mM). Using a combination of low-temperature X-ray diffractometry and thermal analysis, the lyophilization process parameters were optimized. Infra-red spectra revealed hydrogen bonding interaction between PVP and MLT, while BHB crystallized as BHB.0.25 H2O in the final lyophile. The formulation improved survival in a rat model of hemorrhagic shock. Based on the increase in rate of survival and longer survival time compared to untreated animals, we conclude that this formulation can serve as a promising first line of treatment for hemorrhagic shock.

AB - Hemorrhagic shock, caused by trauma, is a leading cause of preventable death. A combination treatment of D-β-hydroxybutyrate (BHB) and melatonin (MLT), in dimethyl sulfoxide - water, increased survival. A freeze-dried BHB–MLT formulation, with a short reconstitution time, has been developed. This intravenous formulation, prepared with an aqueous vehicle, completely eliminated dimethyl sulfoxide, thereby avoiding the potential problems associated with this solvent. The poor aqueous solubility of MLT necessitated the use of polyvinylpyrrolidine (PVP) as a complexing agent. Thus the prelyophilization solution contained BHB (2 M), MLT (21.5 mM) and PVP (40 mM). Using a combination of low-temperature X-ray diffractometry and thermal analysis, the lyophilization process parameters were optimized. Infra-red spectra revealed hydrogen bonding interaction between PVP and MLT, while BHB crystallized as BHB.0.25 H2O in the final lyophile. The formulation improved survival in a rat model of hemorrhagic shock. Based on the increase in rate of survival and longer survival time compared to untreated animals, we conclude that this formulation can serve as a promising first line of treatment for hemorrhagic shock.

KW - Beta hydroxybutyrate

KW - Hemorrhagic shock

KW - Lyophilization

KW - Melatonin

KW - Resuscitation fluid

UR - http://www.scopus.com/inward/record.url?scp=85039163206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039163206&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2017.12.024

DO - 10.1016/j.ijpharm.2017.12.024

M3 - Article

C2 - 29274369

AN - SCOPUS:85039163206

SN - 0378-5173

VL - 537

SP - 162

EP - 171

JO - International journal of pharmaceutics

JF - International journal of pharmaceutics

IS - 1-2

ER -

Development and in vivo evaluation of a novel lyophilized formulation for the treatment of hemorrhagic shock

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this